A tissue cage model in calves for studies on pharmacokinetic/pharmacodynamic interactions of antimicrobials

International Journal of Antimicrobial Agents

Volumn 22, Issue 4, 2003, Pages 429-438

  Greko, Christina ^a   Finn, Maria ^a   Öhagen, Patrik ^b   Franklin, Anders ^a   Bengtsson, Björn ^a  

^a NATIONAL VETERINARY INSTITUTE   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

In vivo models; Mannheimia; Penicillin; Pharmacodynamics; Tissue cages

Indexed keywords

ANTIINFECTIVE AGENT; PENICILLIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; CATTLE; CONTROLLED STUDY; DRUG EFFECT; IMPLANTATION; IN VIVO STUDY; INJECTION; MALE; MANNHEIMA HAEMOLYTICA; MINIMUM INHIBITORY CONCENTRATION; MODEL; MONITORING; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SIMULATION; TIME; TISSUE;

EID: 0041290225     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00112-2     Document Type: Article

References (29)

1. MacGowan A., Bowker K. Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. Int. J. Antimicrob. Agents. 19:2002;291-298.
2. Andes D., Craig W.A. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents. 19:2002;261-268.
3. Andes D., Craig W.A. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 46:2002;1665-1670.
4. Clarke C.R. Tissue-chamber modelling systems - applications in veterinary medicine. J. Vet. Pharmacol. Ther. 12:1989;349-368.
5. Rylander M., Brorson J.E., Holm S.E., Norrby R. Studies on some variables influencing aminoglycoside efficacy in vivo and in vitro. Scand. J. Infect. Dis. 13:1981;217-225.
6. van Etta L.L., Peterson L.R., Fasching C.E., Gerding D.N. Effect of the ratio of surface area to volume on the penetration of antibiotics into extravascular spaces in an in vitro model. J. Infect. Dis. 146:1982;423-428.
7. Bengtsson B., Bredberg U., Luthman J. Mathematical description of the concentration of oxytetracycline and penicillin-G in tissue cages in calves as related to the serum concentration. J. Vet. Pharmacol. Ther. 15:1992;202-216.
8. Bengtsson B., Greko C. Simulation of concentration-profiles of benzyl-penicillin, enrofloxacin and dihydrostreptomycin in tissue cages in calves. J. Vet. Pharmacol. Ther. 25:2002;389-392.
9. NCCLS. Methods for determining bactericidal activity of antimicrobial agents. Approved Guideline. Document M26-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 1999.
10. Bengtsson B., Luthman J., Jacobsson S.-O. Evaluation of a tissue cage model for use in cattle. Acta Vet. Scand. 25:1984;480-494.
11. Rowland M., Tozer T.N. Clinical Pharmacokinetics: Concepts and Applications. 2nd ed. 1989;141 Lea & Febiger, Philadelphia, PA.
12. Chapin-Robertsson K., Edberg S.C. Measurement of antibiotics in human body fluids: techniques and significance. Lorian V. Antibiotics in Laboratory Medicine. 1991;295-366 Williams/Wilkins, Baltimore/London.
13. FDA. Code of federal regulations. Title 21. US Food and Drug Administration, 1977.
14. Zak O., O'Reilly T. Animal models in the evaluation of antimicrobial agents. Antimicrob. Agents Chemother. 35:1991;1527-1531.
15. Zimmerli W. Experimental models in the investigation of device-related infections. J. Antimicrob. Chemother. 31:1993;97-102.
16. Zimmerli W., Lew P.D., Waldvogel F.A. Pathogenesis of foreign body infection: evidence for a local granulocyte defect. J. Clin. Invest. 73:1984;1191-1200.
17. Zimmerli W., Waldvogel F.A., Vadeaux P., Nydegger U.E. Pathogenesis of foreign body infection: description and characteristics of an animal model. J. Infect. Dis. 146:1982;487-497.
18. Widmer A.F., Wiestner A., Frei R., Zimmerli W. Killing of non-growing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob. Agents Chemother. 35:1991;741-746.
19. Erlendsdottir H., Knudsen J.D., Odenholt I., et al. Penicillin pharmacodynamics in four experimental pneumococcal infection models. Antimicrob. Agents Chemother. 45:2001;1078-1085.
20. Ackermann M.R., Brogden K. Response of the ruminant respiratory tract to Mannheimia (Pasteurella) haemolytica. Microb. Infect. 2:2000;1079-1088.
21. Clarke C.R., Short C.R., Corstvet R.E., Nobles D. Interaction between Pasteurella haemolytica, sulfadiazine/trimethoprim, and bovine viral diarrhea virus. Am. J. Vet. Res. 50:1989;1557-1565.
22. MacGowan A., Rogers C., Bowker K. The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens. J. Antimicrob. Chemother. 46:2000;163-170.
23. Firsov A.A., Vostrov S.N., Shevchenko A.A., Cornaglia G. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1997;1281-1287.
24. Firsov A.A., Lubenko I.Y., Portnoy Y.A., Zinner S.H., Vostrov S.N. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrob. Agents Chemother. 45:2001;927-931.
25. Rolinson G. The significance of protein binding of antibiotics in antibacterial chemotherapy. J. Antimicrob. Chemother. 6:1980;311-317.
26. Craig W.A. Pharmacokinetic/pharmacodynamic indices: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1998;1-12.
27. Vogelman B., Gudmundsson S., Legget J., Turnidge J., Ebert S., Craig W.A. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:1988;831-847.
28. Gunderson B.W., Ross G.H., Ibrahim K.H., Rotschafer J.C. What do we really know about antibiotic pharmacodynamics? Pharmacotherapy, Part 2. 21:(10):2001;302S-318S.
29. Lavoie G., Bergeron M. Influence of four modes of administration on penetration of aztreonam, cefuroxime and ampicillin into interstitial fluid and fibrin clots and on in vivo efficacy against Haemophilus influenzae. Antimicrob. Agents Chemother. 28:1985;404-412.